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age age was 69.2 years (SD10.1) and the proportion of men was slightly higher
(54.4%). The hypoglycemia incidence was higher in patients with than without
renal insufficiency (10.8% vs. 3.6%; p0.001). Similarly, the metabolic acidosis in-
cidencewas higher in patients with thanwithout renal insufficiency (1.9% vs. 0.9%;
p0.001). Renal insufficiency in diabetic patients was associated with increased
hypoglycemia [OR: 3.3 (95% CI: 2.8 – 3.9)], and metabolic acidosis [OR: 2.2 (95% CI:
1.5 – 3.2)].CONCLUSIONS:A significant proportion of diabetic patientswith chronic
renal failure experienced hypoglycemia or metabolic acidosis. Treatment strate-
gies for these patients that minimize the risk of these complications should be
considered.
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OBJECTIVES: In China, an estimated 90 million adults are diabetic. An out-patient
clinic physician in a comprehensive hospital sees an average of 50 patients per day.
Patients but not physicians maintain the medical records. Investigators are not
used to electronic data acquiring systems. All these factors present challenges for
conducting quality outcomes research. We recently conducted “Nationwide As-
sessment of Cardiovascular Risk Factors in Chinese Patients with Type 2 Diabetes”,
whichwas aimed to enroll 25000 non-institutional patients nation-wide. In order to
ensure high quality and efficiency of the study, a multifaceted data quality control
process was implemented and evaluated. METHODS: For enrolled patients who
signed informed consent form, investigators were first required to report the orig-
inal patient information on a “Patient Record Form” which served as source docu-
ments, and subsequently to enter the data into aweb-based electronic data capture
system (VitalEDC, VSRI), which performs instantaneous edit checks and generates
real time data query. All investigational sites received frequent onsite monitoring
and auditing when frequent data query occurred or when 50% enrollment
achieved. Additionally, a 10% of the patient records at each site were randomly
selected for a remote source document verification (rSDV). RESULTS: A total of 734
investigators from 103 hospitals across 6 regions of China participated in this
study, and 25817 patientswere enrolledwithin 8months. Among enrolled patients,
100% the data were retrieved, 4,590,00 data records were evaluated, over 3000
unique querieswere generated, only 1.5% (377 out of 25,817) of the patients’ records
were excluded from analyses due to unexplainable queries of pre-defined key
information. CONCLUSIONS: The large sheer volume and rising epidemic of car-
diometabolic and other chronic diseases demand well controlled epidemiological
and comparative effectiveness research in China. Despite challenges, multifaceted
measures of quality control could yield relatively satisfactory outcomes.
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OBJECTIVES:To systematically examine the efficacy and safety of liraglutide 1.2mg
once-daily and exenatide 10mcg twice daily indirectly using meta-analysis of ran-
domized controlled trials (RCTs) involving a common comparator. METHODS: A
systematic review of the literature andmeta-analysiswas conducted. PUBMED and
MEDLINE (January 2000 – July 2011) were searched to identify English-language
randomized trials. Keywords included type 2 diabetes, liraglutide or exenatide, and
randomized controlled trials. Inclusion criteria were RCTs 12 weeks in duration,
type 2 diabetes patients18 years old, involving liraglutide 1.2mg once daily or
exenatide 10mcg twice daily. Meta-analysis was conducted for the following out-
comes: change from baseline in HbA1c, systolic blood pressure, weight and the
number of hypoglycemic episodes. Data were extracted and tabulated by two in-
dependent reviewers and differences were solved by consensus. 41 RCTs were
identified and 16 RCTswere included for further review. Only 10 RCTswith placebo
as common comparators had sufficient information andwere included in the anal-
ysis. Weighted mean differences (WMD) and their 95% confidence intervals were
calculated as appropriate. STATA 11.0 (StataCorp, College Station, Tex) was used to
perform the meta-analysis. RESULTS: Liraglutide 1.2mg once daily reduced HbA1c
1.10% more than placebo (p0.001); exenatide 10mcg twice daily reduced HbA1c
0.60% more than placebo, but not statistically significant (p0.723); liraglutide
1.2mg reduced weight 0.18kg more than placebo (p0.060),and exenatide reduced
weight 0.53kg more than placebo (p0.084); The rate of moderate hypoglycemia
associated with liraglutide 1.2mg was 2.93% in comparison to placebo; The rate of
moderate hypoglycemia associated with exenatide 10mcg was 9.22% in compari-
son to placebo. CONCLUSIONS: Indirect comparison of liraglutide 1.2mg once daily
and exenatide 10mcg twice daily suggest that in comparison to exenatide 10mcg,
liraglutide 1.2mg provided greater improvement in HbA1c, with fewer hypoglyce-
mia episodes.
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OBJECTIVES: Angiotensin Receptor Blockers (ARBs) are indicated for the preven-
tion and treatment of kidney disease in patients with Type 2 Diabetes Mellitus
(T2DM), with established efficacy for nephropathy outcomes. Randomized Con-
trolled Trials (RCTs) have also shown the benefit of using ARBs on cardiovascular
outcomes in patients with T2DM. Results from the ROADMAP trial raised concerns
of increased risk of cardiovascular death with olmesartan. Currently available
ARBs differ in terms of potency and surmountable versus insurmountable block-
ade; therefore, not all of them provide the same benefits and harms. In the absence
of published direct comparative studies, however, an indirect comparison among
these agents is necessary to inform clinical decisionmaking.METHODS:A system-
atic literature search was conducted in PubMed and Cochrane Central Register of
Controlled Trials through September 2011 for RCTs evaluating ARBs in patients
with T2DM. Outcomes of interest were cardiovascular death, all-cause mortality,
and cardiovascular morbidity and mortality. Outcomes were initially pooled using
standard random-effects methods producing odds ratios (OR) and 95% confidence
intervals (CI). Adjusted indirect comparisons between agents using pooled esti-
mateswere thenperformedusing Song’smethodwhen a common comparatorwas
available, typically a placebo. RESULTS:A total of 10,833 patients from 7 RCTswere
analyzed. Compared to olmesartan, candesartan offered statistically significant
protection against cardiovascular death (OR 0.14, 95%CI 0.03 - 0.72), while irbesar-
tan trended towards protection (OR 0.22, 95%CI 0.05 - 1.02). No significant differ-
ence was found between candesartan and irbesartan in cardiovascular death (OR
0.64, 95%CI 0.31 to 1.34). No significant differences were found between any agents
for all-cause mortality or cardiovascular morbidity or mortality. CONCLUSIONS:
Differences in outcomes may exist between ARBs in patients with T2DM, so head-
to-head clinical trials are required to confirm the findings of this adjusted indirect
comparison analysis.
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OBJECTIVES:Comparing the efficacy and safety of liraglutide 1.2mg once dailywith
other hypoglycemic agents in adults with type 2 diabetes through systematic re-
view and meta-analysis of randomized controlled trials. METHODS: A systematic
review of the literature and meta-analysis was conducted. PUBMED and MEDLINE
(Jan 2000 – July 2011) were searched to identify English-language randomized con-
trol trials. Keywords included: type 2 diabetes, liraglutide, and randomized con-
trolled trials. Inclusion criteria were: RCTs 12 weeks in duration, type 2 diabetes
patients 18 years old, comparing liraglutide 1.2mg once daily with placebo or
other active diabetic medications. Meta-analysis was conducted for the following
outcomes: change from baseline in HbA1c, systolic blood pressure and weight as
well as the number of hypoglycemic episodes. Two reviewers independently as-
sessed trials for inclusion and extracted data. Differences were solved by consen-
sus. 41 RCTswere identified and 5 RCTsmet the inclusion criteria. The comparators
were rosiglitazone, glimepiride, placebo and sitagliptin, and were collectively de-
fined as the “comparators”. HbA1c, weight and systolic blood pressure were ana-
lyzed as weighted mean differences (WMD), and the number of hypoglycemic ep-
isodes as relative risks (RR). STATA 11.0 (StataCorp, College Station, Tex) was used
to perform themeta-analysis. RESULTS: In comparison to the “comparator group”,
patients receiving liraglutide 1.2mg reduced HbA1c by 0.54%more (95% confidence
interval, CI-0.81 to -0.28, p0.001); weight loss with liraglutide 1.2mg was 0.54 kg
more than with comparators ( 95% CI-0.72 to -0.36, p0.001); liraglutide 1.2mg
reduced systolic pressure 0.14mmHg more than the comparators (95% CI-0.22 to
-0.06, p0.001); Hypoglycemia episodeswere similar between liraglutide 1.2mg and
the comparators (RR0.86, 95%CI: 0.39 to 1.93, p0.722). CONCLUSIONS: Liraglu-
tide 1.2mg once daily is effective in glycemic control, has the advantage of promot-
ing weight loss and reducing systolic blood pressure versus the comparators for
treating type 2 diabetes.
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OBJECTIVES:Healthcare Effectiveness Data and Information Set (HEDIS) measures
are used to rate health plan performance; HEDIS quality of diabetes care measures
include glycated hemoglobin (HbA1c) categories 7% or 8%, which define good
control, and 9%, which defines poor control. Dapagliflozin, a sodium glucose
cotransporter 2 inhibitor, is under clinical development for the treatment of type 2
diabetes mellitus (T2DM). We assessed the effect of dapagliflozin on achieving
HbA1c outcomes by HEDIS categories.METHODS: Pooled data for dapagliflozin 10
mg/day (N1066) vs placebo (N1257) from nine 24-week, phase 3, randomized,
placebo-controlled trials in patients with T2DM, including monotherapy
(NCT00528372, NCT00736879) and add-on to metformin (NCT00528879,
NCT00855166), glimepiride (NCT00680745), pioglitazone (NCT00683878), or insulin
(NCT00673231), or initial combination with metformin (NCT00859898,
NCT00643851) trials, were analyzed. Adjusted mean change in HbA1c from base-
line to week 24 with dapagliflozin vs placebo was determined for patients with
baseline HbA1c of 8%, 8% to9%, and 9%. Additionally, the proportions of
patients achieving HEDIS HbA1c categories of 7%, 8%, and 9% were assessed.
RESULTS: Placebo-subtracted adjusted mean changes in HbA1c (95% CI) at 24
weeks with dapagliflozin were –0.45% (–0.56%, –0.33%), –0.62% (–0.75%, –0.48%),
and –0.78% (–0.93%, –0.63%) for patients with baseline HbA1c 8%, 8% to9%,
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and 9%, respectively. Compared with placebo, more patients achieved HbA1c
7% (39.4% vs 24.4%) and 8% (79.5% vs 60.6%) and fewer patients remained at or
worsened to HbA1c 9% (4.2% vs 13.9%) with dapagliflozin. CONCLUSIONS: Dapa-
gliflozin 10 mg/day reduced HbA1c across all baseline HbA1c categories; greater
reductions were seen in patients with higher baseline HbA1c. Substantially more
patients attained HEDIS HbA1c categories of7% and8% and substantially fewer
patients remained at orworsened toHbA1c9%with dapagliflozin, comparedwith
placebo. Collectively, dapagliflozin provided better glycemic control than placebo
over a range of HbA1c levels.
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OBJECTIVES: To evaluate the long-term clinical and economic consequences of
saxagliptin in comparison with sulphonylurea available in the Russian market.
METHODS: The analysis is based on the Cardiff Long Term Model (Clarke et al.
2004). Three scenarios were developed and tested. Scenario 1 “trial based scenario”
(S1) the active treatment is saxagliptin (Onglyza®) added to metformin (MET),
which is compared to MET plus sulphonylurea (SU); input data are derived from
study D1680C00001 (Goke et al. 2010). Scenario 2 “real world scenario” (S2). Efficacy
and safety data taken from study D1680C00001, the cohort was taken from the
Russian Federal Diabetes Patient Register, time horizon was set to 40 years, HbA1c
threshold of 9.0% was assumed. Scenario 3 “MET monotherapy scenario” (S3). Ef-
ficacy and safety data taken from a study of DeFronzo et al. 2009. Patient demo-
graphic characteristics were the same as in Scenario 2; time horizon - nine years as
in the base case scenario 1. The cost-effectiveness analysis was performed from
the government health care system’s perspective. The costs applied were based on
prices listed in the essential drug list (MoH 2010) and official standards of treatment
developed by expert groups at the Ministry of Health level (Russian Federation).
RESULTS: In S1 - MET plus saxagliptin was associated with an incremental cost-
effectiveness ratio (ICER) of Russian Roubles (RUB) 38,840 per QALY gained, and
RUB 7,142,690 per life year gained (LYG) versus SU. In S2 - ICER of RUB 104,153 per
QALY gained and RUB 9,884,121 per life year. In S3 - ICER resulted in RUB 20,353,081
perQALYandRUB 29,044,346 per life year gained.CONCLUSIONS: In both scenarios
(1 and 2), assuming a willingness to pay threshold of RUB 800’000, saxagliptin
would be considered cost-effective in the Russian setting.
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OBJECTIVES: To assess the efficacy and safety of DPP-4 inhibitors, including sita-
gliptin, saxagliptin, vildagliptin and linagliptin, in type 2 diabetic patients.
METHODS: Both published and unpublished randomized controlled trials (RCTs)
for type 2 diabetic patients were selected if they: 1) compared DPP-4 inhibitors with
either placebo or another hypoglycemic; 2) had study duration of  12 weeks; and
3) had at least one baseline and post-treatment efficacy and/or safety outcome.
RESULTS: A total of 62 articles met the inclusion criteria. Seven of these trials
involved Japanese patients, but inclusion resulted in significant heterogeneity (I2
82%). Exclusion of these 7 trials resulted in a reduction of heterogeneity (I259%)
with a more stable pooled effect size. Analyses of the non-Japanese studeis (n55
RCTs) indicated that, compared to placebo, DPP-4 inhibitors were associatedwith a
reduction in hemoglobin (Hb) A1c (weightedmean difference (WMD) -0.65%; 95%
CI, -0.71 to -0.60) but a higher risk of hypoglycemia (Odds ratio (OR)  1.30; 95% CI,
1.01 to 1.68). A separate analysis of the 7 Japanese studies showed that, compared
to placebo, DPP-4 inhibitorswere associatedwith a greater reduction inHbA1c than
non-Japanese patients (WMD -1.67%; 95% CI, -1.89 to -1.44; P 0.05) and a non-
significant increase in risk of hypoglycemia (OR, 1.41; 95% CI, 0.51 to 3.88). When
comparing DPP-4 inhibitors to active comparators, the I2 was still high after sepa-
rating out Japanese studies. In the 17 active comparator trials, there was no signif-
icant difference in HbA1c reduction (WMD 0.04%; 95% CI, -0.09 to 0.16) or risk of
hypoglycemia (OR 0.60; 95% CI, 0.22 to 1.61) for DPP-4 inhibitors compared to
other anti-diabetic medications. CONCLUSIONS: Differences in efficacy and safety
were observed between Japanese and non-Japanese patients. The extent of HbA1c
reduction was more than doubled in trials including Japanese populations com-
pared to non-Japanese populations.
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OBJECTIVES: To evaluate, in a US managed care setting, health outcomes among
patients with type 2 diabetes mellitus (T2DM) initiating basal insulin therapy via
disposable penwith insulin glargine (GLA-P) or insulin detemir (DET-P).METHODS:
Using the claim database from a US health plan (InVision™), T2DM patients initi-
ating GLA-P or DET-P were included if they were18 years, had continuous health
plan coverage for 6months before (baseline) and 1-year after initiation (follow-up),
with 1 prescription for oral antidiabetic drugs (OADs) and/or exenatide, but no
insulin use, during baseline. To minimize selection bias, stringent 1:1 propensity
score matching was used to balance baseline characteristics of the two cohorts.
Outcomesmeasures included 1-year treatment persistence and adherence, hemo-
globin A1c (A1C), hypoglycemia-related events, healthcare utilization and costs.
RESULTS: A totla of 5828 matched patients were included (n2914 in each cohort;
female 44.4%, baselinemean age 54.4 years; Charlson comorbidity index 0.55; num-
ber of OADs 2.60). During 1-year follow-up, patients initiating GLA-P, compared
with DET-P, were more persistent (58.8 vs. 44.1%, P0.001) and adherent (adjusted
medication possession ratio 0.68 vs. 0.66, P0.002) with treatment, had lower daily
insulin doses (DACON) (29.2 vs. 32.5 units/day, P0.012), similar rates of hypogly-
cemia-related events (5.9 vs. 6.6%, P0.281), lower diabetes prescription costs
(mean $3,142 vs. $3,372, P0.043) and marginally lower total health care costs
(mean $30,364 vs. $33,109, P0.086). Among patients with A1C data available
(GLA-P n356, DET-P n332), A1C at 1-year follow-up was 8.14% in GLA-P vs. 8.50%
in DET-P (P0.007), reflecting A1C reduction from baseline of 1.03 vs.0.86%
(P0.260). CONCLUSIONS: This real-world comparative study suggested that
among T2DM patients initiating basal analog insulins using disposable pen, com-
paredwithDET-P, GLA-Pmight be associatedwith increased treatment persistence
and adherence, similar rates of hypoglycemia, lower DACON and healthcare costs
during 1-year follow-up. This, however, should be confirmed in future pragmatic
randomized clinical trials.
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OBJECTIVES: Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin re-
ceptor blockers (ARBs) are recommended to reduce albuminuria, a risk factor for
nephropathy and all-cause mortality. The objective of the study was to compare
ACEIs and ARBs for development of end-stage renal disease (ESRD) development
and all-cause mortality in veteran patients with type 2 diabetes. METHODS: This
was a retrospective cohort study utilizing data in years 2002-2007 from the national
Department of Veterans Affairs (VA) databases. To be included in the sample pa-
tients had to be newly-diagnosed, new users of ACEIs or ARBs, and have a baseline
measure of albuminuria. Multivariate logistic regression models that assessed ef-
fect of ACEIs and ARBs on ESRD and all-cause mortality were estimated with con-
trols for risk factors of ESRD and all-causemortality, Elixhauser comorbidities, and
location of care. Propensity scores were used to adjust for differences in baseline
characteristics between ACEI and ARB patients. RESULTS:A total of 20,876 patients
using ACEIs (n18,947) or ARBs (n1929) met inclusion criteria. Mean follow-up
was two years. No significant differences were found between ACEIs and ARBs for
ESRD (1.12 [95% CI0.19-6.72]) and all-cause mortality (0.86 [95% CI0.24-3.07]).
Some comorbidities, however, had higher adjusted odds for ESRD (liver disease
odds ratio 7.40 [95% CI2.91-18.87]; fluid and electrolyte disorders odds ratio 7.71
[95% CI3.46-17.17]; deficiency anemias odds ratio 5.81 [95% CI2.40-14.09]) or
all-cause mortality (history of myocardial infarction odds ratio 2.85 [95% CI1.26-
6.46]), underlining the importance of prevention of these conditions.
CONCLUSIONS: There were no significant differences in ESRD and all-cause mor-
tality betweenACEIs and ARBs in this study that included patients from every state
in the United States, the District of Columbia, and Puerto Rico. Additionally, this
study shows that clinicians should focus educational efforts on disease prevention
due to downstream effects of certain conditions in patients with type 2 diabetes.
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OBJECTIVES: Turner syndrome (TS) is a chromosomal disorder that has total or
partial absence of chromosome X and haploinsufficiency of the SHOX gene. Fur-
thermore, it is associated with short stature with particular phenotype and hypo-
gonadism. Several studies have shown that the use of recombinant human growth
hormone (GH) in girls with TS raises final height. The aim of this study was to
describe the characteristics of a cohort of girls with TS diagnosed and treated with
GH in Colombia.METHODS: A cohort of 22 girls with TS, who entered to the drug-
international epidemiological record (KIGS) between 2004 and 2010were tracked in
Colombia. Girlswere diagnosedwith short stature and treatedwithGH therapy and
followed-up for 2 years. Tracking measures were: the time of starting therapy,
treatment regimens and clinical outcomes were estimated in terms of height mea-
sured by standard deviation units (SDS) and velocity growth in cm per year. Cohort
data was compared against literature findings published for girls treated on GH
with TS (Ranke MB et al 1988) and girls without GH treatment and TS (Tanner JM et
al 1976). RESULTS: Girls started GH therapy at a mean age of 7.03 years with a dose
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